Profile data is unavailable for this security.
About the company
Scholar Rock Holding Corporation is a late-stage biopharmaceutical company. It is focused on advancing treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases. Its transforming growth factor beta (TGFb) superfamily biology, its novel molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. Its product candidate, apitegromab, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Apitegromab is being developed as a potential first muscle-targeted therapy for the treatment of SMA. Its products include SRK-439, SRK-181, SRK-373 and SRK-256. SRK-181 is a selective inhibitor of the activation of latent TGFb1, is being developed for the treatment of cancers.
- Revenue in USD (TTM)0.00
- Net income in USD-264.16m
- Incorporated2017
- Employees196.00
- LocationScholar Rock Holding Corp301 BINNEY STREET, 3RD FLOORCAMBRIDGE 02142United StatesUSA
- Phone+1 (857) 259-3860
- Fax+1 (302) 655-5049
- Websitehttps://scholarrock.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xenon Pharmaceuticals Inc | 7.50m | -251.45m | 2.55bn | 316.00 | -- | 3.62 | -- | 340.29 | -3.22 | -3.22 | 0.0960 | 9.19 | 0.009 | -- | 1.58 | 23,734.18 | -30.25 | -22.00 | -31.27 | -22.93 | -- | -- | -3,352.61 | -1,082.36 | -- | -- | 0.00 | -- | -- | -- | -28.48 | -- | 19.92 | -- |
| Crinetics Pharmaceuticals Inc | 760.00k | -328.25m | 2.79bn | 437.00 | -- | 2.22 | -- | 3,673.25 | -3.82 | -3.82 | 0.0088 | 13.41 | 0.0007 | -- | 0.0963 | 1,739.13 | -28.06 | -36.96 | -29.43 | -39.20 | -- | -- | -43,191.05 | -7,785.98 | -- | -- | 0.00 | -- | -74.11 | -2.73 | -39.10 | -- | 50.86 | -- |
| Apogee Therapeutics Inc | 0.00 | -205.39m | 2.83bn | 196.00 | -- | 4.11 | -- | -- | -3.59 | -3.59 | 0.00 | 11.55 | 0.00 | -- | -- | 0.00 | -26.71 | -- | -27.69 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -116.88 | -- | -- | -- |
| Immunovant Inc | 0.00 | -413.84m | 2.90bn | 362.00 | -- | 4.08 | -- | -- | -2.74 | -2.74 | 0.00 | 4.16 | 0.00 | -- | -- | 0.00 | -57.37 | -47.00 | -62.46 | -51.13 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -59.58 | -- | 89.57 | -- |
| Metsera Inc | 0.00 | -265.84m | 3.09bn | 74.00 | -- | 6.11 | -- | -- | -2.87 | -2.87 | 0.00 | 4.82 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0165 | -- | -- | -- | -343.01 | -- | -- | -- |
| MoonLake Immunotherapeutics | 0.00 | -145.21m | 3.14bn | 100.00 | -- | 7.61 | -- | -- | -2.30 | -2.30 | 0.00 | 6.42 | 0.00 | -- | -- | 0.00 | -27.49 | -- | -28.77 | -- | -- | -- | -- | -- | -- | -9,486.42 | 0.1504 | -- | -- | -- | -230.31 | -- | -- | -- |
| Kymera Therapeutics Inc | 58.89m | -240.88m | 3.14bn | 208.00 | -- | 3.71 | -- | 53.36 | -3.10 | -3.10 | 0.761 | 12.07 | 0.0659 | -- | 5.35 | 313,218.10 | -26.97 | -23.82 | -28.82 | -27.88 | -- | -- | -409.07 | -240.35 | -- | -- | 0.0044 | -- | -40.11 | 74.20 | -52.32 | -- | 89.02 | -- |
| Protagonist Therapeutics Inc | 207.80m | 56.19m | 3.16bn | 124.00 | 67.29 | 4.59 | 54.08 | 15.23 | 0.7586 | 0.7586 | 3.29 | 11.13 | 0.303 | -- | 1.27 | 1,649,214.00 | 8.19 | -7.11 | 8.67 | -7.93 | -- | -- | 27.04 | -21.29 | -- | -- | 0.00 | -- | 624.06 | 351.71 | 448.54 | -- | 6.98 | -- |
| Viking Therapeutics Inc | 0.00 | -128.24m | 3.17bn | 45.00 | -- | 3.74 | -- | -- | -1.15 | -1.15 | 0.00 | 7.54 | 0.00 | -- | -- | 0.00 | -13.98 | -22.44 | -14.39 | -23.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -28.02 | -- | -- | -- |
| Scholar Rock Holding Corp | 0.00 | -264.16m | 3.42bn | 196.00 | -- | 10.93 | -- | -- | -2.54 | -2.54 | 0.00 | 3.29 | 0.00 | -- | -- | 0.00 | -78.29 | -45.06 | -88.09 | -51.62 | -- | -- | -- | -1,134.62 | -- | -- | 0.1374 | -- | -- | -- | -48.56 | -- | -49.93 | -- |
| ACADIA Pharmaceuticals Inc | 996.28m | 228.88m | 3.51bn | 653.00 | 15.27 | 4.58 | 14.48 | 3.52 | 1.37 | 1.37 | 5.97 | 4.58 | 1.00 | 1.87 | 9.94 | 1,525,701.00 | 23.03 | -13.15 | 33.80 | -16.74 | 92.04 | 94.49 | 22.97 | -16.00 | 2.80 | -- | 0.00 | -- | 31.85 | 23.08 | 469.50 | -- | -14.26 | -- |
| Arcellx Inc | 76.81m | -162.42m | 3.70bn | 163.00 | -- | 8.87 | -- | 48.18 | -2.99 | -2.99 | 1.42 | 7.57 | 0.1076 | -- | -- | 471,220.80 | -22.75 | -27.24 | -26.90 | -32.13 | -- | -- | -211.46 | -212.50 | -- | -- | 0.00 | -- | -2.16 | -- | -51.86 | -- | 28.52 | -- |
| Akero Therapeutics Inc | 0.00 | -269.44m | 4.13bn | 69.00 | -- | 3.81 | -- | -- | -3.75 | -3.75 | 0.00 | 13.60 | 0.00 | -- | -- | 0.00 | -26.06 | -36.86 | -27.01 | -38.94 | -- | -- | -- | -- | -- | -- | 0.0317 | -- | -- | -- | -66.09 | -- | -- | -- |
| Krystal Biotech Inc | 333.45m | 123.96m | 4.13bn | 275.00 | 34.49 | 4.20 | 31.64 | 12.40 | 4.15 | 4.15 | 11.17 | 34.07 | 0.346 | 1.11 | 4.45 | 1,212,535.00 | 12.86 | -4.81 | 13.77 | -5.07 | 93.20 | -- | 37.18 | -41.51 | 9.27 | -- | 0.00 | -- | 473.02 | -- | 715.58 | -- | -7.91 | -- |
| Cytokinetics, Inc. | 19.22m | -615.26m | 4.14bn | 498.00 | -- | -- | -- | 215.39 | -5.31 | -5.31 | 0.1658 | -2.23 | 0.0186 | -- | 13.51 | 38,590.36 | -59.38 | -45.50 | -67.48 | -50.38 | -- | -- | -3,201.47 | -748.37 | -- | -16.68 | 1.68 | -- | 145.34 | -7.22 | -12.03 | -- | 8.32 | -- |
Data as of Jul 03 2025. Currency figures normalised to Scholar Rock Holding Corp's reporting currency: US Dollar USD
54.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Mar 2025 | 13.75m | 14.68% |
| T. Rowe Price Associates, Inc. (IM)as of 31 Mar 2025 | 8.81m | 9.41% |
| BlackRock Fund Advisorsas of 31 Mar 2025 | 6.03m | 6.44% |
| The Vanguard Group, Inc.as of 31 Mar 2025 | 4.67m | 4.99% |
| Redmile Group LLCas of 31 Mar 2025 | 4.40m | 4.70% |
| SSgA Funds Management, Inc.as of 31 Mar 2025 | 3.13m | 3.35% |
| Eventide Asset Management LLCas of 31 Mar 2025 | 2.66m | 2.84% |
| Polar Capital LLPas of 31 Mar 2025 | 2.58m | 2.76% |
| Bellevue Asset Management AGas of 31 Mar 2025 | 2.51m | 2.68% |
| Adage Capital Management LPas of 31 Mar 2025 | 2.02m | 2.16% |
More ▼
Data from 31 Mar 2025 - 31 Mar 2025Source: FactSet Research Systems Inc.
